Spinocerebellar ataxia

Patient and health professional perspectives on whether and how patents affect access to clinical genetic testing

Ashton Powell, Subhashini Chandrasekharan, Robert Cook-Deegan

Research output: Contribution to journalReview article

14 Citations (Scopus)

Abstract

Genetic testing for spinocerebellar ataxia is used in diagnosis of rare movement disorders. Such testing generally does not affect treatment, but confirmation of mutations in a known gene can confirm diagnosis and end an often years-long quest for the cause of distressing and disabling symptoms. Through interviews and a web forum hosted by the National Ataxia Foundation, patients and health professionals related their experiences with the effect of patents on access to genetic testing for spinocerebellar ataxia. In the United States, Athena Diagnostics holds either a patent or an exclusive license to a patent in the case of six spinocerebellar ataxia variants (spinocerebellar ataxia 1-3 and 6-8) and two other hereditary ataxias (Friedreich's Ataxia and Early Onset Ataxia). Athena has enforced its exclusive rights to spinocerebellar ataxia-related patents by sending notification letters to multiple laboratories offering genetic testing for inherited neurological conditions, including spinocerebellar ataxia. Roughly half of web forum respondents had decided not to get genetic tests. Price, coverage and reimbursement by insurers and health plans, and fear of genetic discrimination were the main reasons cited for deciding not to get tested. Price was cited as an access concern by the physicians, and as sole US provider, coverage and reimbursement depend on having payment agreements between Athena and payers. In cases in which payers do not reimburse, the patient is responsible for payment, although some patients can apply to the voluntary Athena Access and Patient Protection Plan offered by the company.

Original languageEnglish (US)
JournalGenetics in Medicine
Volume12
Issue number4 SUPPL.
DOIs
StatePublished - Apr 2010
Externally publishedYes

Fingerprint

Spinocerebellar Ataxias
Patents
Genetic Testing
Health
Ataxia
Machado-Joseph Disease
Spinocerebellar Degenerations
Friedreich Ataxia
Insurance Carriers
Movement Disorders
Licensure
Fear
Interviews
Physicians
Mutation

Keywords

  • Ataxia
  • Athena Diagnostics
  • Genetic testing
  • Intellectual property
  • Patents
  • Spinocerebellar ataxia

ASJC Scopus subject areas

  • Genetics(clinical)

Cite this

Spinocerebellar ataxia : Patient and health professional perspectives on whether and how patents affect access to clinical genetic testing. / Powell, Ashton; Chandrasekharan, Subhashini; Cook-Deegan, Robert.

In: Genetics in Medicine, Vol. 12, No. 4 SUPPL., 04.2010.

Research output: Contribution to journalReview article

@article{ebc4225265b94b1ab71bf84e52561a86,
title = "Spinocerebellar ataxia: Patient and health professional perspectives on whether and how patents affect access to clinical genetic testing",
abstract = "Genetic testing for spinocerebellar ataxia is used in diagnosis of rare movement disorders. Such testing generally does not affect treatment, but confirmation of mutations in a known gene can confirm diagnosis and end an often years-long quest for the cause of distressing and disabling symptoms. Through interviews and a web forum hosted by the National Ataxia Foundation, patients and health professionals related their experiences with the effect of patents on access to genetic testing for spinocerebellar ataxia. In the United States, Athena Diagnostics holds either a patent or an exclusive license to a patent in the case of six spinocerebellar ataxia variants (spinocerebellar ataxia 1-3 and 6-8) and two other hereditary ataxias (Friedreich's Ataxia and Early Onset Ataxia). Athena has enforced its exclusive rights to spinocerebellar ataxia-related patents by sending notification letters to multiple laboratories offering genetic testing for inherited neurological conditions, including spinocerebellar ataxia. Roughly half of web forum respondents had decided not to get genetic tests. Price, coverage and reimbursement by insurers and health plans, and fear of genetic discrimination were the main reasons cited for deciding not to get tested. Price was cited as an access concern by the physicians, and as sole US provider, coverage and reimbursement depend on having payment agreements between Athena and payers. In cases in which payers do not reimburse, the patient is responsible for payment, although some patients can apply to the voluntary Athena Access and Patient Protection Plan offered by the company.",
keywords = "Ataxia, Athena Diagnostics, Genetic testing, Intellectual property, Patents, Spinocerebellar ataxia",
author = "Ashton Powell and Subhashini Chandrasekharan and Robert Cook-Deegan",
year = "2010",
month = "4",
doi = "10.1097/GIM.0b013e3181d67e44",
language = "English (US)",
volume = "12",
journal = "Genetics in Medicine",
issn = "1098-3600",
publisher = "Lippincott Williams and Wilkins",
number = "4 SUPPL.",

}

TY - JOUR

T1 - Spinocerebellar ataxia

T2 - Patient and health professional perspectives on whether and how patents affect access to clinical genetic testing

AU - Powell, Ashton

AU - Chandrasekharan, Subhashini

AU - Cook-Deegan, Robert

PY - 2010/4

Y1 - 2010/4

N2 - Genetic testing for spinocerebellar ataxia is used in diagnosis of rare movement disorders. Such testing generally does not affect treatment, but confirmation of mutations in a known gene can confirm diagnosis and end an often years-long quest for the cause of distressing and disabling symptoms. Through interviews and a web forum hosted by the National Ataxia Foundation, patients and health professionals related their experiences with the effect of patents on access to genetic testing for spinocerebellar ataxia. In the United States, Athena Diagnostics holds either a patent or an exclusive license to a patent in the case of six spinocerebellar ataxia variants (spinocerebellar ataxia 1-3 and 6-8) and two other hereditary ataxias (Friedreich's Ataxia and Early Onset Ataxia). Athena has enforced its exclusive rights to spinocerebellar ataxia-related patents by sending notification letters to multiple laboratories offering genetic testing for inherited neurological conditions, including spinocerebellar ataxia. Roughly half of web forum respondents had decided not to get genetic tests. Price, coverage and reimbursement by insurers and health plans, and fear of genetic discrimination were the main reasons cited for deciding not to get tested. Price was cited as an access concern by the physicians, and as sole US provider, coverage and reimbursement depend on having payment agreements between Athena and payers. In cases in which payers do not reimburse, the patient is responsible for payment, although some patients can apply to the voluntary Athena Access and Patient Protection Plan offered by the company.

AB - Genetic testing for spinocerebellar ataxia is used in diagnosis of rare movement disorders. Such testing generally does not affect treatment, but confirmation of mutations in a known gene can confirm diagnosis and end an often years-long quest for the cause of distressing and disabling symptoms. Through interviews and a web forum hosted by the National Ataxia Foundation, patients and health professionals related their experiences with the effect of patents on access to genetic testing for spinocerebellar ataxia. In the United States, Athena Diagnostics holds either a patent or an exclusive license to a patent in the case of six spinocerebellar ataxia variants (spinocerebellar ataxia 1-3 and 6-8) and two other hereditary ataxias (Friedreich's Ataxia and Early Onset Ataxia). Athena has enforced its exclusive rights to spinocerebellar ataxia-related patents by sending notification letters to multiple laboratories offering genetic testing for inherited neurological conditions, including spinocerebellar ataxia. Roughly half of web forum respondents had decided not to get genetic tests. Price, coverage and reimbursement by insurers and health plans, and fear of genetic discrimination were the main reasons cited for deciding not to get tested. Price was cited as an access concern by the physicians, and as sole US provider, coverage and reimbursement depend on having payment agreements between Athena and payers. In cases in which payers do not reimburse, the patient is responsible for payment, although some patients can apply to the voluntary Athena Access and Patient Protection Plan offered by the company.

KW - Ataxia

KW - Athena Diagnostics

KW - Genetic testing

KW - Intellectual property

KW - Patents

KW - Spinocerebellar ataxia

UR - http://www.scopus.com/inward/record.url?scp=77951436850&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77951436850&partnerID=8YFLogxK

U2 - 10.1097/GIM.0b013e3181d67e44

DO - 10.1097/GIM.0b013e3181d67e44

M3 - Review article

VL - 12

JO - Genetics in Medicine

JF - Genetics in Medicine

SN - 1098-3600

IS - 4 SUPPL.

ER -